Navigation Links
Tortoise and the hare: New drug stops rushing cancer cells, slow and steady healthy cells unharmed
Date:3/2/2012

The American Cancer Society estimates that 44,000 new cases of pancreatic cancer will be diagnosed this year and that 37,000 people will die from the disease. These are not strong odds. A new drug, rigosertib, allows pancreatic cancer cells to rush through replication and then stops them cold, killing them in in the middle of a step called M phase. Healthy cells that don't rush are unharmed.

Data from a phase I clinical trial of patients with advanced pancreatic cancer and additional solid tumors recently published in the journal Clinical Cancer Research shows the strategy has promise. While the goal of any phase I trial is to establish the dosage that best balances effectiveness against side effects, 11 of the 19 patients treated achieved stable disease, which lasted for a median of 113 days.

"Really, the drug takes one of cancer's greatest strengths and turns it into a weakness," says Wells Messersmith, MD, co-leader of the Developmental Therapeutics Program at the University of Colorado Cancer Center and the clinical trial's national principal investigator.

Instead of going with the flow of the natural cell cycle, cancer cells amplify two signals PLK1 and PI3K which allows them to blast through the cell cycle and divide much more quickly. In the process, they break this step of the natural cell cycle, known as the G1 regulatory mechanism, and thus depend on the kick of PLK1 and P13K to push at a frenzied pace through replication.

It's specifically these two signals, PLK1 and PI3K, that rigosertib targets. With these signals turned off, cancer cells get stuck and die in the stage of the cell cycle called M phase while healthy cells that stuck to the slower, natural method of division chug past unharmed.

Wells Messersmith, MD, co-leader of the Developmental Therapeutics Program at the University of Colorado Cancer Center

"This one-two punch, targeting these two distinct signaling pathways, allows us to interfere twice with cancer cells' ability to replicate," Messersmith says. And it also allows doctors to target cancers that may have evolved resistance to one or the other target.


'/>"/>

Contact: Garth Sundem
garth.sundem@ucdenver.edu
University of Colorado Denver
Source:Eurekalert

Related biology news :

1. Extinct for 150 years, an iconic Galpagos giant tortoise species lives
2. Tortoise populations can withstand fires every 30 years
3. Giant tortoises show rewilding can work
4. In the race of life, better an adaptable tortoise than a fit hare
5. New study shows how giant tortoises, alligators thrived in High Arctic 50 million years ago
6. Madagascars radiated tortoise threatened with extinction
7. New theory shows that neither birth nor death stops a flock
8. Path to oxygen in Earths atmosphere: long series of starts and stops
9. Athletic girls more likely to have impaired bone structure if menstrual cycle stops
10. Policing stops cheaters from dominating groups of cooperative bacteria
11. Researchers find drug that stops progression of Parkinsons disease in mice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... , March 28, 2017 The ... Hardware (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, ... Region - Global Forecast to 2022", published by MarketsandMarkets, ... 2016 and is projected to reach USD 75.64 Billion ... and 2022. The base year considered for the study ...
(Date:3/24/2017)... 24, 2017 The Controller General of Immigration from ... Abdulla Algeen have received the prestigious international IAIR Award for the ... Continue Reading ... ... Controller Abdulla Algeen (small picture on the right) have received the IAIR ...
(Date:3/23/2017)... The report "Gesture Recognition and Touchless Sensing Market by Technology (Touch-based ... to 2022", published by MarketsandMarkets, the market is expected to be worth USD ... 2022. Continue Reading ... ... ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. ... Cancer Research, London (ICR) and University ... SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma ... MUK nine . The University of Leeds ... partly funded by Myeloma UK, and ICR will perform the ...
(Date:10/10/2017)... ... 2017 , ... San Diego-based team building and cooking events company, Lajollacooks4u, has ... The bold new look is part of a transformation to increase awareness, appeal to ... period. , It will also expand its service offering from its signature gourmet cooking ...
(Date:10/10/2017)... 10, 2017 International research firm Parks Associates announced ... at the TMA 2017 Annual Meeting , October 11 in ... residential home security market and how smart safety and security products impact ... Parks Associates: Smart Home ... "The residential security market has ...
(Date:10/9/2017)... DIEGO , Oct. 9, 2017  BioTech ... biological mechanism by which its ProCell stem cell ... critical limb ischemia.  The Company, demonstrated that treatment ... amount of limbs saved as compared to standard ... the molecule HGF resulted in reduction of therapeutic ...
Breaking Biology Technology: